Seagen stock stays tied to Pfizer's integration.

By Julia Smith, Sector & Peers desk. Reviewed on July 7, 2026 at 6:48 p.m. ET.

Seagen Inc (Acquired) (ISIN US8166361055) no longer trades as an independent listed stock. The company was acquired by Pfizer, so the surviving market angle is the role Seagen's oncology assets play inside Pfizer's pipeline and commercial mix.

What the name still means

Seagen built its reputation in antibody-drug conjugates, a cancer drug class designed to deliver chemotherapy payloads more precisely to tumor cells. That product logic still matters because it explains why the franchise was attractive enough to become part of Pfizer's oncology push.

Why investors care

For US investors, the key reference point is Pfizer rather than a live SGEN quote, since Seagen is no longer an active standalone US listing. Any fresh market read now comes from how Pfizer reports integration, oncology revenue, and pipeline progress in its own disclosures.

Flagship product line

Padcev and other cancer therapies remained the core commercial assets that gave Seagen its strategic value. The business model centered on specialty oncology medicines, with development, licensing, and commercialization all aimed at high-value cancer markets.

Market context

Because Seagen is acquired, there is no current standalone stock price to cite for SGEN. The relevant market context is Pfizer's broader valuation and execution around oncology assets as of July 7, 2026.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.